Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 1999

Conditions
HIV InfectionsHodgkin's Disease
Interventions
DRUG

Vinblastine sulfate

DRUG

Dacarbazine

DRUG

Filgrastim

DRUG

Bleomycin sulfate

DRUG

Doxorubicin hydrochloride

Trial Locations (8)

35294

Alabama Therapeutics CRS, Birmingham

60611

Northwestern University CRS, Chicago

63112

St. Louis ConnectCare, Infectious Diseases Clinic, St Louis

432101228

The Ohio State Univ. AIDS CRS, Columbus

462025250

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

900331079

USC CRS, Los Angeles

Unknown

Washington U CRS, St Louis

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH